IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional Under 37 C.F.R. 1.53(b) Application of: : Bono-Colombie et al.

Prior Application Serial No.: 10/044,223

Prior Filing Date: November 20, 2001

Group Art Unit: 1625

Examiner: Jane T. Fan

USE OF 4-SUBSTITUTED TETRAHYDRO-PYRIDINES FOR MAKING MEDICINES ACTING ON

TGF-BETA 1

Mail Stop Patent Application **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label Number: EL676469648US

Date of Deposit: I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Name

CITATION OF REFERENCES

Enclosed herewith on an Information Disclosure Statement by Applicant (Form PTO-1449) is a list of references for consideration by the Examiner.

This Information Disclosure Statement is being filed concurrently with the aboveidentified application and, consequently, no fee or statement pursuant to 37 C.F.R. §1.97(c) or (d) is required. Furthermore, pursuant to 37 C.F.R. §1.98(d), copies of the listed references are not being provided as they were previously cited by or submitted to the Examiner in prior application Serial No. 10/044,223, filed November 20, 2001, which are relied upon for an earlier filing date under 35 U.S.C. §120.

Paul E. Dupont Reg. No. 27,435

Address:

Patent Department Sanofi-Synthelabo Inc. 9 Great Valley Parkway Malvern, PA 19355

Telephone No. (610) 889-6338 Facsimile: (610) 889-8799



(Use several sheets if necessary)

				Sheet 1 of 1.
orm PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. IVD 1000-3	SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Bono-Colombie et al.	. — — — — — — — — — — — — — — — — — — —	
	DI AFFLICANI	FILING DATE	GROUP	

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,281,606	01/25/94	Guzzi et al.			
	5,618,822	04/08/97	Guzzi et al.			
	4,521,428	06/04/85	Nisato et al.			
	5,292,745	03/08/94	Heaulme et al.			
	5,229,389	07/20/93	Coude et al.			
	5,270,320	12/14/93	Coude et al.			
	5,462,945	10/31/95	Guzzi et al.			
	5,468,753	11/21/95	Coude et al.			
	6,034,090	03/07/00	Baroni et al.			
	5,981,754	11/09/99	Badoni et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	<u>Trans</u> Yes	lation No
EP 0498718	08/12/92	EPO			105	X
EP 0458696	11/27/91	EPO				Х
WO 97/01536	01/16/97	PCT				Х
EP 0645755	03/29/95	EPO			·	
WO 93/11107	06/10/93	PCT				
EP 0458697	11/27/91	EPO				Х
EP 101381	02/22/84	EPO				Х
WO 96/21449	07/18/96	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	The state of the s				
	J. H. Prehn, Medline Abstract No. 96226070				
	J. P. Terranova, Medline Abstract No. 97011603 J. Mathieu, Medline Abstract No. 97112057				
	Derwent Patent Abstract No. 199709				
EXAMINER	DATE CONSIDERED				
	Initial if citation considered, whether or not citation is in conformance with MPEP 6 and not considered. Include copyof this form with next communication to applicant.	09; Draw line through citation if not in			